The definition of AR in oncogene-driven NSCLC is often extrapolated from EGFR-mutant disease using the Jackman criteria: prior EGFR TKI monotherapy, presence of a sensitizing mutation or clinical benefit, systemic progression on continuous TKI within 30 days, and no intervening systemic therapy [11]. Here, AR is linked to non-small cell lung carcinoma.